538 related articles for article (PubMed ID: 18257603)
21. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.
Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM;
Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715
[TBL] [Abstract][Full Text] [Related]
22. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
23. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
24. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
25. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.
Feldman H; Gauthier S; Hecker J; Vellas B; Subbiah P; Whalen E;
Neurology; 2001 Aug; 57(4):613-20. PubMed ID: 11524468
[TBL] [Abstract][Full Text] [Related]
26. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
27. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
28. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
Matthews HP; Korbey J; Wilkinson DG; Rowden J
Int J Geriatr Psychiatry; 2000 Aug; 15(8):713-20. PubMed ID: 10960883
[TBL] [Abstract][Full Text] [Related]
29. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
Rogers SL; Friedhoff LT
Eur Neuropsychopharmacol; 1998 Feb; 8(1):67-75. PubMed ID: 9452942
[TBL] [Abstract][Full Text] [Related]
31. Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer's Disease.
Chase TN; Farlow MR; Clarence-Smith K
Neurotherapeutics; 2017 Apr; 14(2):405-416. PubMed ID: 28138837
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.
Salloway S; Ferris S; Kluger A; Goldman R; Griesing T; Kumar D; Richardson S;
Neurology; 2004 Aug; 63(4):651-7. PubMed ID: 15326237
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.
Tariot P; Salloway S; Yardley J; Mackell J; Moline M
BMC Res Notes; 2012 Jun; 5():283. PubMed ID: 22681723
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.
Rogers SL; Friedhoff LT
Dementia; 1996; 7(6):293-303. PubMed ID: 8915035
[TBL] [Abstract][Full Text] [Related]
36. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML
Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447
[TBL] [Abstract][Full Text] [Related]
37. Combination treatment in Alzheimer's disease: results of a randomized, controlled trial with cerebrolysin and donepezil.
Alvarez XA; Cacabelos R; Sampedro C; Couceiro V; Aleixandre M; Vargas M; Linares C; Granizo E; García-Fantini M; Baurecht W; Doppler E; Moessler H
Curr Alzheimer Res; 2011 Aug; 8(5):583-91. PubMed ID: 21679156
[TBL] [Abstract][Full Text] [Related]
38. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
39. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
Prasher VP; Huxley A; Haque MS;
Int J Geriatr Psychiatry; 2002 Mar; 17(3):270-8. PubMed ID: 11921156
[TBL] [Abstract][Full Text] [Related]
40. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]